5.37
-0.01 (-0.19%)
| Penutupan Terdahulu | 5.38 |
| Buka | 5.36 |
| Jumlah Dagangan | 1,185,453 |
| Purata Dagangan (3B) | 8,924,157 |
| Modal Pasaran | 419,159,648 |
| Harga / Buku (P/B) | 1.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Replimune Group, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Boxer Capital Management, Llc | 30 Jun 2025 | 2,211,341 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 22.00 (HC Wainwright & Co., 309.68%) | Beli |
| Median | 4.00 (-25.51%) | |
| Rendah | 2.00 (BMO Capital, -62.76%) | Jual |
| Purata | 7.00 (30.35%) | |
| Jumlah | 2 Beli, 4 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 3.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 23 Jul 2025 | 2.00 (-62.76%) | Jual | 3.34 |
| Barclays | 23 Jul 2025 | 3.00 (-44.13%) | Pegang | 3.34 |
| JP Morgan | 22 Jul 2025 | 9.00 (67.60%) | Pegang | 2.81 |
| 16 Jul 2025 | 19.00 (253.82%) | Beli | 12.63 | |
| Jefferies | 22 Jul 2025 | 6.00 (11.73%) | Beli | 2.81 |
| Leerink Partners | 22 Jul 2025 | 3.00 (-44.13%) | Pegang | 2.81 |
| Wedbush | 22 Jul 2025 | 4.00 (-25.51%) | Pegang | 2.81 |
| HC Wainwright & Co. | 03 Jul 2025 | 22.00 (309.68%) | Beli | 9.40 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Sep 2025 | Pengumuman | Replimune Announces Type A Meeting Scheduled with FDA |
| 27 Aug 2025 | Pengumuman | Shareholders SueWallSt in New Class Action Against Replimune Group, Inc. - Act Now |
| 26 Aug 2025 | Pengumuman | Shareholders SueWallSt in New Class Action Against Replimune Group, Inc. - Act Now |
| 20 Aug 2025 | Pengumuman | Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations |
| 07 Aug 2025 | Pengumuman | Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update |
| 22 Jul 2025 | Pengumuman | Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma |
| 11 Jul 2025 | Pengumuman | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |